* OmniAb Inc OABI.OQ OABI.O is expected to report
results on
March 30.
* The Emeryville California-based company is expected to
report
revenue of $24.726 million, according to the mean estimate from
5 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for OmniAb Inc is for
earnings of 2 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for OmniAb Inc
is
$10.5, above its last closing price of $3.37.
This summary was machine generated March 28 at 20:38 GMT. All
figures in US dollars unless otherwise stated